Malaria Parasites Evade Drugs Using Young Blood Cells: Study

Researchers at the Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB) in India have uncovered a new mechanism allowing malaria parasites to evade artemisinin, the leading anti-malarial drug. The study, published as an *Editor’s Choice* article in *The Journal of Infectious Diseases*, reveals that reticulocytes—young red blood cells—provide a protective environment, enabling parasites to withstand drug-induced stress. Led by Christeen Davis and colleagues, the team found that the host cell’s antioxidant defenses, rather than genetic mutations in the parasite, play a key role in treatment resistance. The research involved collaboration between BRIC-RGCB, IISER Thiruvananthapuram, Cosmopolitan Hospital (Thiruvananthapuram), and CSIR-National Chemical Laboratory (Pune). Senior author Dr. Rajesh Chandramohanadas explained that parasites exploit the natural defenses of reticulocytes to survive drug exposure, highlighting the importance of host-parasite interactions in treatment outcomes. This discovery may explain why some patients experience delayed parasite clearance despite standard therapy, even without known resistance markers. BRIC-RGCB Director Dr. Beena Pillai emphasized that understanding these interactions could lead to improved malaria treatment strategies. The findings suggest future therapies might target both the parasite and the cellular environment supporting its survival. The study is particularly relevant for vulnerable populations, such as children, anemic patients, and individuals recovering from blood loss or infections, who often have elevated reticulocyte levels. With malaria affecting millions globally, this research offers new insights into persistent infections and potential ways to enhance drug effectiveness. The team believes their work could pave the way for more targeted treatments, addressing gaps in current anti-malarial strategies.